Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Celiac Disease
- Main trialPhase 2
- “The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.”In the company’s words, NCT07239336 on ClinicalTrials.gov
Other drugs for Celiac Disease
- Larazotide AcetateInterlude Biopharma Co. · Phase 3
- FB102Forte Biosciences, Inc. · Phase 2
- ZED1227Dr. Falk Pharma GmbH · Phase 2
- AmlitelimabSanofi · Phase 2
- TEV-53408Teva Branded Pharmaceutical Products R&D LLC · Phase 2
Coming up1
- 15 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 15 Jun 2027 | Study of DONQ52 in Active Celiac Disease | |
| Phase 1Completed | 9 Aug 2024 | Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026